(2R,3R,4S,5S,6R)-6-[[(2S,3R,4S,5R,6R)-3,4,5-Trihydroxy-6-[[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxymethyl]oxan-2-yl]oxymethyl]oxane-2,3,4,5-tetrol

Term ID

CHEBI:155248

Synonyms

beta-D-galacto-hexopyranosyl-(1->6)-alpha-D-galacto-hexopyranosyl-(1->6)-alpha-D-galacto-hexopyranosyl-(1->6)-beta-D-gluco-hexopyranose
Gal(b1-6)Gal(a1-6)Gal(a1-6)b-Glc

Definition

References

glygen:G92001FG
glytoucan:G92001FG

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from (2R,3R,4S,5S,6R)-6-[[(2S,3R,4S,5R,6R)-3,4,5-Trihydroxy-6-[[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxymethyl]oxan-2-yl]oxymethyl]oxane-2,3,4,5-tetrol

Phenotype where environments contain (2R,3R,4S,5S,6R)-6-[[(2S,3R,4S,5R,6R)-3,4,5-Trihydroxy-6-[[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxymethyl]oxan-2-yl]oxymethyl]oxane-2,3,4,5-tetrol

Phenotype modified by environments containing (2R,3R,4S,5S,6R)-6-[[(2S,3R,4S,5R,6R)-3,4,5-Trihydroxy-6-[[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxymethyl]oxan-2-yl]oxymethyl]oxane-2,3,4,5-tetrol

Phenotype affecting (2R,3R,4S,5S,6R)-6-[[(2S,3R,4S,5R,6R)-3,4,5-Trihydroxy-6-[[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxymethyl]oxan-2-yl]oxymethyl]oxane-2,3,4,5-tetrol

Human Disease Model